C-4VZNReGENE
small molecules, evolutionary biology, aging mechanisms
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-4VZN
C-4VZNC-4VZNsmall molecules, evolutionary biology, aging mechanisms
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ReGENE small molecules, evolutionary biology, aging mechanisms
ReGENE develops small molecule therapies intended to prevent and treat aging-associated diseases by targeting mechanisms that drive aging. Its approach is rooted in evolutionary biology and focuses on understanding biological processes that have shaped human longevity. The company describes its pipeline as therapies for aging-associated non-communicable diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
ReGENE — Early mechanism · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic